Study open
Dementia
Symptoms and impact
Dementia, and Alzheimer's in particular, causes profound changes in both the person's thinking and behavior. People with Alzheimer's or other forms of dementia may not only experience psychotic symptoms, such as hallucinations and delusions, but also suffer from agitation, agitation and mood swings.
In addition, memory loss, difficulty concentrating and a decline in logical thinking often cause confusion and frustration. Brain damage, stress, anxiety, certain medications and environmental factors can exacerbate these psychotic symptoms.
Need for appropriate assistance
There is currently a lack of effective treatments for dementia, causing significant emotional and practical challenges for those around the patient. Often family caregivers must watch helplessly, requiring them to provide additional care and support. There is an urgent need for targeted medical and psychosocial help - not only for the person with dementia, but also for the people who care for them on a daily basis.
New research
ANIMA Research will soon launch a groundbreaking study to find a treatment for the complex symptoms of dementia. The goal is to improve the well-being of both patients and those around them.
Patients with Alzheimer's disease and their family caregivers can participate in the study, with both being compensated for their participation. The informal caregiver should preferably be a family member who has close contact with the patient. The use of anti-Alzheimer's medication is allowed, but not required.
Interested in participating?
Sign up for the study without obligation at the link below. More info at info.dementie@anima-alken.be.
DOWNLOADS
Target
- Men and women
- Age: 55-90 years old
- (Possibly) suffering from Alzheimer's disease
- Together with caregiver
Program
The studies will start at various times in 2025 and last 20 weeks. Each study is divided into three phases: a preliminary study, a treatment phase and a follow-up phase, during which the effectiveness and safety of the therapy will be closely monitored. After completion, participants may be treated with the new drug for up to a year.
Location
Anima Research Center
Alkerstraat 32Z (Block D)
3570 Alken, Belgium
or
Anima Research Center
Science Park 11-13 UHasselt
3590 Diepenbeek, Belgium
Reimbursement
Any participation in a clinical trial will be reimbursed. Specific information on this will be released after application.